Investing in Vaccines to Mitigate Harm from COVID-19 and Future Pandemics
Rachel Glennerster,
Catherine Che,
Sarrin M. Chethik,
Claire T. McMahon and
Christopher Snyder
No 32984, NBER Working Papers from National Bureau of Economic Research, Inc
Abstract:
This paper evaluates the social value of investing in vaccine research, development, and manufacturing capacity for pandemic preparedness and response. Rapid vaccination during pandemics can significantly reduce mortality, economic losses, and societal disruptions. However, vaccine manufacturers often lack sufficient incentives for speed and capacity expansion. Strategic policies by governments and international organizations could enhance these incentives and improve equitable vaccine distribution.
JEL-codes: I15 I18 L65 (search for similar items in EconPapers)
Date: 2024-09
New Economics Papers: this item is included in nep-hea
Note: DEV EH
References: Add references at CitEc
Citations:
Downloads: (external link)
http://www.nber.org/papers/w32984.pdf (application/pdf)
Access to the full text is generally limited to series subscribers, however if the top level domain of the client browser is in a developing country or transition economy free access is provided. More information about subscriptions and free access is available at http://www.nber.org/wwphelp.html. Free access is also available to older working papers.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberwo:32984
Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w32984
The price is Paper copy available by mail.
Access Statistics for this paper
More papers in NBER Working Papers from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().